Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles 90048, USA.
Cedars-Sinai Cancer Applied Genomics Shared Resource, Cedars-Sinai Medical Center, Los Angeles 90048, USA.
J Control Release. 2023 Sep;361:636-658. doi: 10.1016/j.jconrel.2023.08.001. Epub 2023 Aug 17.
Delivery of therapeutic substances into the brain poses a significant challenge in the treatment of neurological disorders. This is primarily due to the blood-brain barrier (BBB), which restricts access, alongside the limited stability and distribution of these agents within the brain tissue. Here we demonstrate an efficient delivery of microRNA (miRNA) and antisense RNA preferentially to neurons compared to astroglia in the brain of healthy and Alzheimer's disease mice, via disulfide-linked conjugation with poly(ß-L-malic acid-trileucine)-copolymer a biodegradable, amphiphilic, and multivalent platform. By conjugating a D-configured (D3)-peptide (vector) for specific targeting, highly efficient delivery across the BBB is achieved through the Low-Density Lipoprotein Receptor-Related Protein-1 (LRP-1) transcytosis pathway, amyloid beta (Aβ) peptides. Nanodrug distribution was determined by fluorescent labeling and analyzed by microscopy in neurons, astroglia, and in extracellular amyloid plaques typical for Alzheimer's disease. Whereas D-configured BBB-vectors can efficiently target neurons, L-configured (e.g., AP2-peptide) guided vector can only cross BBB but not seem to bind neurons. An analysis of post-injection fluorescence distribution, and RNA-seq followed by real-time PCR validation, confirmed a successful in vivo delivery of morpholino-miRNA-186 nanoconjugates into mouse brain. The size and fluorescence intensity of the intracellular nanodrug particulates were analyzed and verified by a competition with non-fluorescent conjugates. Differentially expressed genes (DEGs) from RNA-seq were identified in the nanodrug injected mice, and the changes of selected DEGs related to Alzheimer's disease were further validated by western blot and real-time PCR. Collectively, these results demonstrated that D3-peptide-conjugated nanopolymer drug is able to achieve neuron-selective delivery of miRNA and can serve as an efficient brain delivery vehicle in Alzheimer's disease (AD) mouse models.
将治疗物质递送到大脑中对于治疗神经疾病是一个重大的挑战。这主要是由于血脑屏障(BBB)限制了物质的进入,并且这些物质在脑组织中的稳定性和分布都很有限。在这里,我们通过与聚(β-L-马来酸-三亮氨酸)-共聚物的二硫键连接,展示了一种有效的方法,可以将 microRNA(miRNA)和反义 RNA 优先递送到健康和阿尔茨海默病小鼠的神经元中,而不是星形胶质细胞中。这种共聚物是一种可生物降解的、两亲性的、多价的平台。通过连接用于特异性靶向的 D 构型(D3)肽(载体),通过 LDLR 相关蛋白-1(LRP-1)转胞吞途径,实现了高效穿过血脑屏障的递送,该途径与淀粉样β(Aβ)肽有关。通过荧光标记和显微镜分析来确定纳米药物的分布,这些分析在神经元、星形胶质细胞和典型的阿尔茨海默病的细胞外淀粉样斑块中进行。虽然 D 构型的 BBB 载体可以有效地靶向神经元,但 L 构型(例如,AP2-肽)引导的载体只能穿过血脑屏障,但似乎不能与神经元结合。对注射后荧光分布的分析以及随后的 RNA-seq 和实时 PCR 验证,证实了体内递送的 morpholino-miRNA-186 纳米复合物成功进入了小鼠大脑。通过与非荧光缀合物竞争,分析和验证了细胞内纳米药物颗粒的大小和荧光强度。从 RNA-seq 中鉴定出差异表达基因(DEGs),并通过 Western blot 和实时 PCR 进一步验证了与阿尔茨海默病相关的选定 DEGs 的变化。总之,这些结果表明,D3-肽缀合的纳米聚合物药物能够实现 miRNA 的神经元选择性递送,并可作为阿尔茨海默病(AD)小鼠模型中的有效脑内递药载体。